Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AZD0171
MSC-1 · 2 trials · 5 indications
The safety and tolerability of study intervention (AZD0171, durvalumab, and standard-of-care chemotherapy) was assessed. The grading scales found in the revised National Cancer Institute CTCAE latest version was utilized for all events with an assigned CTCAE grading. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living (ADL); Grade 4: Life-threatening, urgent intervention required; Grade 5: Death related to AE.
Percentage of participants alive at 12 months after initiation of study intervention per Kaplan- Meier estimate of OS at 12 months.
Assessment of frequency \& severity of adverse events
Determine objective response rate (ORR)
| Arm | Type | Description |
|---|---|---|
| AZD0171 + Durvalumab + chemotherapy | EXPERIMENTAL | Participants will receive AZD0171 (intravenous \[IV\]) along with durvalumab (IV) in combination with standard-of-care chemotherapy IV (gemcitabine and nab-paclitaxel). |
| Dose Escalation | EXPERIMENTAL | Multiple dose levels of MSC-1 treatment once every 3 weeks |
| Dose Expansion | EXPERIMENTAL | MSC-1 treatment at the recommended Phase 2 dose once every 3 weeks |
| Name | Type | Description |
|---|---|---|
| AZD0171 | DRUG | AZD0171 |
| Durvalumab | DRUG | Durvalumab |
| Gemcitabine | DRUG | Chemotherapy (Standard-of-Care) |
| Nab-paclitaxel | DRUG | Chemotherapy (Standard-of-Care) |
| MSC-1 | BIOLOGICAL | humanized monoclonal antibody for intravenous administration |
Inclusion Criteria: * Eastern Cooperative Oncology Group performance status of 0 or 1 at screening/enrolment * Must have a Gustave Roussy Immune Score of 0 or 1 * Participants diagnosed with histologically confirmed metastatic pancreatic adenocarcinoma * Participants must have at least 1 measurable...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
MSC-1 is an investigational monoclonal antibody being developed for the treatment of advanced solid tumors, including pancreatic cancer, non-small cell lung cancer, and ovarian cancer. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
MSC-1 is a monoclonal antibody, but its specific molecular target has not been disclosed in available information. The drug is being studied for its safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity in patients with advanced solid tumors.
MSC-1 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the drug's potential in treating advanced solid tumors.
MSC-1 is in Phase 1 clinical development. A Phase 1 study has been completed, and the drug remains investigational. It has not received FDA approval and is still undergoing clinical evaluation for safety and efficacy in patients with advanced solid tumors.
MSC-1 has been studied in one clinical trial, identified as NCT03490669, which was a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MSC-1 in patients with advanced solid tumors. The trial was completed and enrolled 41 participants.